CMMB - CIK 0001534248
The table below shows Chemomab Therapeutics Ltd.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | $2.33M | $2.46M | $4.39M | $5.14M | $3.31M | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $5.83M | $11.33M | $18.38M | $16.98M | $6.33M | $4.68M |
| SG&A | $3.73M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.41M |
| $7.08M |
| $11.56M |
| $6.03M |
| $1.29M |
| Operating income | -$112.00M | -$103.00M | - | - | - | - |
| Income tax | $0.00 | $0.00 | $0.00 | -$534.00K | $0.00 | $0.00 |
| Net income | -$8.99M | -$13.95M | -$24.22M | -$27.65M | -$12.48M | -$5.95M |
| EPS (diluted) | $0.02 | $0.04 | $0.10 | $0.12 | $0.06 | - |